PTEN phosphatase activity, independent of other PTEN functions, is required to prevent T cell lymphoma
INTRODUCTION
The tumor suppressor gene phosphatase and tensin homolog deleted on chromosome 10 (PTEN) was initially characterized as a lipid phosphatase that directly opposes PI3K signaling.
1,2 PTEN was subsequently shown to additionally possess non-catalytic nuclear functions in its C-terminal domain that help maintain genomic stability. [3] [4] [5] Mutations in PTEN are associated with multiple cancers in humans, including T cell malignancies, [6] [7] [8] [9] [10] [11] [12] and targeted deletion of PTEN in murine T cells results in the development of a T cell malignancy with characteristics of human T-ALL. [13] [14] [15] [16] Interestingly, the most common PTEN-specific mutations which have been detected in primary T-ALL samples are mutational disruptions within the C-terminal region that do not alter phosphatase activity. 7 Moreover, a recent study reported spontaneous tumor development, including T cell lymphomas, in mice harboring a knock-in mutation that causes loss of the PTEN C-terminal region. 17 This has led to the suggestion that the role of PTEN as a tumor suppressor in T cell leukemia is independent of its phosphatase function.
In this study, we address this question using a conditional mouse model which maintains T cell specific expression of a phosphatase-dead PTEN mutant (C124S) in the absence of wild-type PTEN. We find that loss of PTEN phosphatase activity alone is sufficient to enable lymphomagenesis. Furthermore, we show that these lymphomas phenocopy those that develop upon complete loss of PTEN in T cells, 14, 18 including presence of the characteristic t(14;15) translocation. The fact that loss of PTEN phosphatase activity alone is sufficient for occurrence of this specific genetic lesion, suggests that it requires hyper-active PI3K/Akt signaling and is independent of PTEN's nuclear role in promoting Cell lysate preparation, SDS-PAGE, immunoblotting and development using enhanced chemiluminescence were performed as previously described. 14 T cells were fractionated using EasySep (StemCell Technologies). All Abs were purchased from Cell Signaling
Technology. Metaphases were prepared and SKY was analyzed as previously described. 14 Single-chromosome paints specific for mouse chr14 and chr15 were performed and analyzed as previously described.
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Flow cytometry and phospho-flow Monoclonal antibodies were purchased from BD. Cells were stained by standard methods, and events were collected on an LSRII (BD) and analyzed by FlowJo software (Tree Star, Inc). Phospho-flow was performed as previously described.
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RESULTS AND DISCUSSION
As previously reported by our lab and others, 13, 14, 16 mice with a T cell-specific deletion of Fig. 1C-D) . Substantial signaling differences were noted in Akt and its direct targets Foxo1/3a and GSK3β. Other molecules in the PI3K pathway which are not direct targets of Akt, such as mTOR and S6, were less affected, and differences in 4E-BP1 phosphorylation more variable. Phospho-flow was used to evaluate signaling differences of specific populations within the thymus (Fig. 1B) 
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